Achillion Pharmaceut (ACHN) 9.55 $ACHN
Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
GlobeNewswire - Fri Jun 10, 2:30AM CDT
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 -
ACHN: 9.55 (-0.18)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 9.55 (-0.18), JAZZ: 150.76 (-5.26), GRFS: 16.96 (-0.23), PBYI: 33.41 (-0.43)
Achillion to Present at Three Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:02PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at three upcoming investor conferences:
ACHN: 9.55 (-0.18)
Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 5:05AM CDT
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers -
ACHN: 9.55 (-0.18)
Achillion reports 1Q loss
Automated Insights - Tue May 03, 5:19AM CDT
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $18.1 million in its first quarter.
ACHN: 9.55 (-0.18)
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
GlobeNewswire - Tue May 03, 5:05AM CDT
- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 -
ACHN: 9.55 (-0.18)
Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference
GlobeNewswire - Thu Apr 28, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 41 Annual Health Care Conference on Thursday, May 5, 2016 at 1:30 p.m. EDT at The InterContinental Hotel in Boston, MA.
ACHN: 9.55 (-0.18), DB: 15.74 (-0.97)
Can the Uptrend Continue for Achillion Pharmaceuticals (ACHN)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 7:02AM CDT
Investors certainly have to be happy with Achillion Pharmaceuticals, Inc. (ACHN) and its short term performance
ACHN: 9.55 (-0.18)
First Week of December 16th Options Trading For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Tue Apr 19, 9:57AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the December 16th expiration.
ACHN: 9.55 (-0.18)
ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel
GlobeNewswire - Thu Mar 24, 7:09AM CDT
ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced the appointment of Frank Verwiel, MD to its Board of Directors. Over the last 25 years, Dr. Verwiel has amassed a wealth of knowledge across multiple operational, development, and commercial disciplines for both small and large biotechnology and pharmaceutical companies. Most recently, Dr. Verwiel was President and Chief Executive Officer of Aptalis Pharma, Inc. (formerly Axcan Pharma Inc.), which was acquired by Forest Laboratories for $2.9 billion in 2014.
ACHN: 9.55 (-0.18), AVXS: 44.71 (-1.50)
Achillion to Present at Two Upcoming Investor Conferences
GlobeNewswire - Thu Mar 03, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:
ACHN: 9.55 (-0.18)
What's in Store for Intercept (ICPT) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 4:00PM CST
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report fourth-quarter 2015 and full-year results on Feb 23, before the market opens.
AGN: 240.93 (-6.47), ADRO: 11.99 (-0.43), ACHN: 9.55 (-0.18), ICPT: 150.66 (-3.56)
Tuberculosis Therapeutics Development Pipeline Review, H2 2015 Featuring 60 Key Companies
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2fbvp/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Tuberculosis Overview - Therapeutics Development - Pipeline Products for Tuberculosis - Overview - Pipeline Products for Tuberculosis - Comparative Analysis - Tuberculosis - Therapeutics under Development by Companies - Tuberculosis - Therapeutics under Investigation by Universities/Institutes - Tuberculosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Tuberculosis - Products under Development by Companies - Tuberculosis - Products under Investigation by Universities/Institutes - Tuberculosis - Companies Involved in Therapeutics Development - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - BioDiem Ltd - BioLingus AG - Biomar Microbial Technologies - Bioversys AG - Celgene Corporation - Cellceutix Corporation - Chongqing Zhifei Biological Products Co., Ltd. - Ensol Biosciences Inc. - EpiVax, Inc. - FIT Biotech Oy - GangaGen Inc. - GlaxoSmithKline Plc - Globeimmune, Inc. - Hsiri Therapeutics, LLC - Imaxio SA - Immunitor, Inc. - ImmunoBiology Limited - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Microbion Corporation - Microbiotix, Inc. - NEARMEDIC PLUS, Ltd - Novartis AG - Okklo Life Sciences BV - Orchid Chemicals & Pharmaceuticals Ltd - Otsuka Holdings Co., Ltd. - Polymun Scientific Immunbiologische Forschung GmbH - Prokarium Limited - QureTech Bio AB - Sanofi - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/b2...berculosis
JNJ: 117.01 (+0.01), INO: 10.62 (-0.39), ACHN: 9.55 (-0.18), GSK: 40.93 (-1.13), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Why Achillion Pharmaceuticals Shares Crashed 37% in January
Todd Campbell, The Motley Fool - Motley Fool - Thu Feb 04, 2:40PM CST
Image source: Achillion Pharmaceuticals. W hat: Despite announcing a key new hire last month, shares in the clinical-stage drugmaker Achillion Pharmaceuticals dropped 37.3% in January, according to S&P Capital IQ. So what: On Jan....
JNJ: 117.01 (+0.01), GILD: 84.45 (-1.32), ACHN: 9.55 (-0.18), BMY: 72.65 (-0.08)
Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
GlobeNewswire - Wed Feb 03, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016. In addition, Amy Jennings, Ph.D., recently joined the Company and will serve as Senior Vice President of Regulatory Affairs.
ACHN: 9.55 (-0.18)
Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global Eagle Entertainment, LendingClub and Barracuda Networks
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 8:30AM CST
Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global Eagle Entertainment, LendingClub and Barracuda Networks
LC: 4.26 (-0.21), OPK: 9.30 (-0.31), ACHN: 9.55 (-0.18), CUDA: 15.32 (-0.39), ENT: 7.35 (-0.12)
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline Review - H2 2015 Report
M2 - Wed Jan 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/nnv8gp/paroxysmal) has announced the addition of the "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Paroxysmal Nocturnal Hemoglobinuria Overview - Therapeutics Development - Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Overview - Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Comparative Analysis - Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Development by Companies - Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Investigation by Universities/Institutes - Paroxysmal Nocturnal Hemoglobinuria - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Paroxysmal Nocturnal Hemoglobinuria - Products under Development by Companies - Paroxysmal Nocturnal Hemoglobinuria - Products under Investigation by Universities/Institutes - Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development - Achillion Pharmaceuticals, Inc. - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Apellis Pharmaceuticals, Inc. - Epirus Biopharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Ra Pharmaceuticals, Inc. - Regenesance BV - The International Biotechnology Center (IBC) Generium For more information visit http://www.researchandmarkets.com/research/nnv8gp/paroxysmal
ACHN: 9.55 (-0.18), ALXN: 135.61 (-2.63), OMER: 10.75 (-0.09), NVS: 78.94 (-1.57)
A Company's First Profit Can Mean Big Profits to Investors
Kevin Matras - Zacks Investment Research - Tue Jan 26, 2:04PM CST
A Company's First Profit Can Mean Big Profits to Investors
LC: 4.26 (-0.21), OPK: 9.30 (-0.31), ACHN: 9.55 (-0.18), CUDA: 15.32 (-0.39), ENT: 7.35 (-0.12)
Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
GlobeNewswire - Fri Jun 10, 2:30AM CDT
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 -
ACHN: 9.55 (-0.18)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 9.55 (-0.18), JAZZ: 150.76 (-5.26), GRFS: 16.96 (-0.23), PBYI: 33.41 (-0.43)
Achillion to Present at Three Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:02PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at three upcoming investor conferences:
ACHN: 9.55 (-0.18)
Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 5:05AM CDT
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers -
ACHN: 9.55 (-0.18)
Achillion reports 1Q loss
Automated Insights - Tue May 03, 5:19AM CDT
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $18.1 million in its first quarter.
ACHN: 9.55 (-0.18)
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
GlobeNewswire - Tue May 03, 5:05AM CDT
- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 -
ACHN: 9.55 (-0.18)
Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference
GlobeNewswire - Thu Apr 28, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 41 Annual Health Care Conference on Thursday, May 5, 2016 at 1:30 p.m. EDT at The InterContinental Hotel in Boston, MA.
ACHN: 9.55 (-0.18), DB: 15.74 (-0.97)
Can the Uptrend Continue for Achillion Pharmaceuticals (ACHN)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 7:02AM CDT
Investors certainly have to be happy with Achillion Pharmaceuticals, Inc. (ACHN) and its short term performance
ACHN: 9.55 (-0.18)
First Week of December 16th Options Trading For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Tue Apr 19, 9:57AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the December 16th expiration.
ACHN: 9.55 (-0.18)
ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel
GlobeNewswire - Thu Mar 24, 7:09AM CDT
ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced the appointment of Frank Verwiel, MD to its Board of Directors. Over the last 25 years, Dr. Verwiel has amassed a wealth of knowledge across multiple operational, development, and commercial disciplines for both small and large biotechnology and pharmaceutical companies. Most recently, Dr. Verwiel was President and Chief Executive Officer of Aptalis Pharma, Inc. (formerly Axcan Pharma Inc.), which was acquired by Forest Laboratories for $2.9 billion in 2014.
ACHN: 9.55 (-0.18), AVXS: 44.71 (-1.50)
Achillion to Present at Two Upcoming Investor Conferences
GlobeNewswire - Thu Mar 03, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:
ACHN: 9.55 (-0.18)
What's in Store for Intercept (ICPT) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 4:00PM CST
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report fourth-quarter 2015 and full-year results on Feb 23, before the market opens.
AGN: 240.93 (-6.47), ADRO: 11.99 (-0.43), ACHN: 9.55 (-0.18), ICPT: 150.66 (-3.56)
Tuberculosis Therapeutics Development Pipeline Review, H2 2015 Featuring 60 Key Companies
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2fbvp/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Tuberculosis Overview - Therapeutics Development - Pipeline Products for Tuberculosis - Overview - Pipeline Products for Tuberculosis - Comparative Analysis - Tuberculosis - Therapeutics under Development by Companies - Tuberculosis - Therapeutics under Investigation by Universities/Institutes - Tuberculosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Tuberculosis - Products under Development by Companies - Tuberculosis - Products under Investigation by Universities/Institutes - Tuberculosis - Companies Involved in Therapeutics Development - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - BioDiem Ltd - BioLingus AG - Biomar Microbial Technologies - Bioversys AG - Celgene Corporation - Cellceutix Corporation - Chongqing Zhifei Biological Products Co., Ltd. - Ensol Biosciences Inc. - EpiVax, Inc. - FIT Biotech Oy - GangaGen Inc. - GlaxoSmithKline Plc - Globeimmune, Inc. - Hsiri Therapeutics, LLC - Imaxio SA - Immunitor, Inc. - ImmunoBiology Limited - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Microbion Corporation - Microbiotix, Inc. - NEARMEDIC PLUS, Ltd - Novartis AG - Okklo Life Sciences BV - Orchid Chemicals & Pharmaceuticals Ltd - Otsuka Holdings Co., Ltd. - Polymun Scientific Immunbiologische Forschung GmbH - Prokarium Limited - QureTech Bio AB - Sanofi - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/b2...berculosis
JNJ: 117.01 (+0.01), INO: 10.62 (-0.39), ACHN: 9.55 (-0.18), GSK: 40.93 (-1.13), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Why Achillion Pharmaceuticals Shares Crashed 37% in January
Todd Campbell, The Motley Fool - Motley Fool - Thu Feb 04, 2:40PM CST
Image source: Achillion Pharmaceuticals. W hat: Despite announcing a key new hire last month, shares in the clinical-stage drugmaker Achillion Pharmaceuticals dropped 37.3% in January, according to S&P Capital IQ. So what: On Jan....
JNJ: 117.01 (+0.01), GILD: 84.45 (-1.32), ACHN: 9.55 (-0.18), BMY: 72.65 (-0.08)
Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
GlobeNewswire - Wed Feb 03, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016. In addition, Amy Jennings, Ph.D., recently joined the Company and will serve as Senior Vice President of Regulatory Affairs.
ACHN: 9.55 (-0.18)
Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global Eagle Entertainment, LendingClub and Barracuda Networks
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 8:30AM CST
Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global Eagle Entertainment, LendingClub and Barracuda Networks
LC: 4.26 (-0.21), OPK: 9.30 (-0.31), ACHN: 9.55 (-0.18), CUDA: 15.32 (-0.39), ENT: 7.35 (-0.12)
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline Review - H2 2015 Report
M2 - Wed Jan 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/nnv8gp/paroxysmal) has announced the addition of the "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Paroxysmal Nocturnal Hemoglobinuria Overview - Therapeutics Development - Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Overview - Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Comparative Analysis - Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Development by Companies - Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Investigation by Universities/Institutes - Paroxysmal Nocturnal Hemoglobinuria - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Paroxysmal Nocturnal Hemoglobinuria - Products under Development by Companies - Paroxysmal Nocturnal Hemoglobinuria - Products under Investigation by Universities/Institutes - Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development - Achillion Pharmaceuticals, Inc. - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Apellis Pharmaceuticals, Inc. - Epirus Biopharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Ra Pharmaceuticals, Inc. - Regenesance BV - The International Biotechnology Center (IBC) Generium For more information visit http://www.researchandmarkets.com/research/nnv8gp/paroxysmal
ACHN: 9.55 (-0.18), ALXN: 135.61 (-2.63), OMER: 10.75 (-0.09), NVS: 78.94 (-1.57)
A Company's First Profit Can Mean Big Profits to Investors
Kevin Matras - Zacks Investment Research - Tue Jan 26, 2:04PM CST
A Company's First Profit Can Mean Big Profits to Investors
LC: 4.26 (-0.21), OPK: 9.30 (-0.31), ACHN: 9.55 (-0.18), CUDA: 15.32 (-0.39), ENT: 7.35 (-0.12)
